Cargando…
Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer
BACKGROUND: Pancreatic cancer (PC) has the lowest 5-year survival rate; therefore, new early screening methods and therapeutic targets are still urgently required. Emerging technologies such as metabolomic-based liquid biopsy may contribute to the field. We found aberrant lactate dehydrogenase A (LD...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944301/ https://www.ncbi.nlm.nih.gov/pubmed/33708985 http://dx.doi.org/10.21037/atm-21-295 |
_version_ | 1783662660916609024 |
---|---|
author | Jiang, Wenna Qiao, Lu Zuo, Duo Qin, Di Xiao, Jiawei An, Haohua Wang, Yanhui Zhang, Xinwei Jin, Yu Ren, Li |
author_facet | Jiang, Wenna Qiao, Lu Zuo, Duo Qin, Di Xiao, Jiawei An, Haohua Wang, Yanhui Zhang, Xinwei Jin, Yu Ren, Li |
author_sort | Jiang, Wenna |
collection | PubMed |
description | BACKGROUND: Pancreatic cancer (PC) has the lowest 5-year survival rate; therefore, new early screening methods and therapeutic targets are still urgently required. Emerging technologies such as metabolomic-based liquid biopsy may contribute to the field. We found aberrant lactate dehydrogenase A (LDHA) signaling to be an unfavorable biomarker for PC. METHODS: A total of 9 genes of the glycolysis pathway were detected by enrichment analysis in the PC Gene Expression Omnibus (GEO) dataset. The relationship between LDHA/pyruvate kinase (PKM)/fructose biphosphate aldolase A (ALDOA)/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and patient survival was analyzed by Kaplan-Meier plotting analysis of The Cancer Genome Atlas (TCGA). The detection of changing metabolites in the serum of PC patients was performed using a nuclear magnetic resonance (NMR) spectrometer. RESULTS: We found LDHA was an independent predictor of overall survival (OS) in PC patients (P<0.001). Consistent with genetic aberrance of LDHA, we identified significant alterations in patients’ glycolysis-related metabolites, including upregulation of lactic acid and downregulation of pyruvic acid. A 0.956 area under the curve (AUC) was achieved using the combinative metabolites score of lactic acid, pyruvic acid, citric acid, and glucose to distinguish PC from healthy controls. CONCLUSIONS: Aberrant LDHA signaling is an unfavorable biomarker for PC and consequential metabolic changes constitute potential diagnostic signatures of PCs. |
format | Online Article Text |
id | pubmed-7944301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-79443012021-03-10 Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer Jiang, Wenna Qiao, Lu Zuo, Duo Qin, Di Xiao, Jiawei An, Haohua Wang, Yanhui Zhang, Xinwei Jin, Yu Ren, Li Ann Transl Med Original Article BACKGROUND: Pancreatic cancer (PC) has the lowest 5-year survival rate; therefore, new early screening methods and therapeutic targets are still urgently required. Emerging technologies such as metabolomic-based liquid biopsy may contribute to the field. We found aberrant lactate dehydrogenase A (LDHA) signaling to be an unfavorable biomarker for PC. METHODS: A total of 9 genes of the glycolysis pathway were detected by enrichment analysis in the PC Gene Expression Omnibus (GEO) dataset. The relationship between LDHA/pyruvate kinase (PKM)/fructose biphosphate aldolase A (ALDOA)/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and patient survival was analyzed by Kaplan-Meier plotting analysis of The Cancer Genome Atlas (TCGA). The detection of changing metabolites in the serum of PC patients was performed using a nuclear magnetic resonance (NMR) spectrometer. RESULTS: We found LDHA was an independent predictor of overall survival (OS) in PC patients (P<0.001). Consistent with genetic aberrance of LDHA, we identified significant alterations in patients’ glycolysis-related metabolites, including upregulation of lactic acid and downregulation of pyruvic acid. A 0.956 area under the curve (AUC) was achieved using the combinative metabolites score of lactic acid, pyruvic acid, citric acid, and glucose to distinguish PC from healthy controls. CONCLUSIONS: Aberrant LDHA signaling is an unfavorable biomarker for PC and consequential metabolic changes constitute potential diagnostic signatures of PCs. AME Publishing Company 2021-02 /pmc/articles/PMC7944301/ /pubmed/33708985 http://dx.doi.org/10.21037/atm-21-295 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Jiang, Wenna Qiao, Lu Zuo, Duo Qin, Di Xiao, Jiawei An, Haohua Wang, Yanhui Zhang, Xinwei Jin, Yu Ren, Li Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer |
title | Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer |
title_full | Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer |
title_fullStr | Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer |
title_full_unstemmed | Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer |
title_short | Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer |
title_sort | aberrant lactate dehydrogenase a signaling contributes metabolic signatures in pancreatic cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944301/ https://www.ncbi.nlm.nih.gov/pubmed/33708985 http://dx.doi.org/10.21037/atm-21-295 |
work_keys_str_mv | AT jiangwenna aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer AT qiaolu aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer AT zuoduo aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer AT qindi aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer AT xiaojiawei aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer AT anhaohua aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer AT wangyanhui aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer AT zhangxinwei aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer AT jinyu aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer AT renli aberrantlactatedehydrogenaseasignalingcontributesmetabolicsignaturesinpancreaticcancer |